These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 5723963)

  • 61. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Role of immunologic activity of host in radiotherapy].
    Tsuchiya T
    Gan No Rinsho; 1983 Oct; 29(13):1499-505. PubMed ID: 6608014
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Assessing growth and response to therapy in murine tumor models.
    Reynolds CP; Sun BC; DeClerck YA; Moats RA
    Methods Mol Med; 2005; 111():335-50. PubMed ID: 15911989
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The incorporation of 67 Ga in normal and malignant cells and its dependence on growth rate.
    Bichel P; Hansen HH
    Br J Radiol; 1972 Mar; 45(531):182-4. PubMed ID: 5015266
    [No Abstract]   [Full Text] [Related]  

  • 65. Effect of plasma cell tumor on antibody production by mouse spleen cells.
    Carlson PJ; Smith F
    Proc Soc Exp Biol Med; 1968 Jan; 127(1):212-5. PubMed ID: 4171307
    [No Abstract]   [Full Text] [Related]  

  • 66. [Experimental plasmacytoma in the mouse: atypical nuclei].
    Sessa A; Bracchi G; Invernizzi F
    Haematol Lat; 1969; 12(3):771-7. PubMed ID: 5396835
    [No Abstract]   [Full Text] [Related]  

  • 67. [A new family of distributions for the parametric analysis of data on the life expectancy of tumor carriers].
    Kamynina TV; Iakovlev AIu; Anisimov VN; Zhukovskaia NV
    Vopr Onkol; 1987; 33(6):23-8. PubMed ID: 3617597
    [No Abstract]   [Full Text] [Related]  

  • 68. Electron microscopic study of the mammary tumor agent in plasma cell tumors.
    Dalton AJ; Potter M
    J Natl Cancer Inst; 1968 Jun; 40(6):1375-85. PubMed ID: 5660273
    [No Abstract]   [Full Text] [Related]  

  • 69. [Growth kinetics of nonexponentially growing tumors and the life expectancy of tumor carriers].
    Konradov AA; Dronova LM; Erokhin VN; Korman DB
    Izv Akad Nauk SSSR Biol; 1987; (4):527-35. PubMed ID: 3668064
    [No Abstract]   [Full Text] [Related]  

  • 70. Characteristics of microcirculation in experimental tumours.
    Krylova NV
    Bibl Anat; 1969; 10():301-3. PubMed ID: 5407377
    [No Abstract]   [Full Text] [Related]  

  • 71. Platelet adherence to tumor cells "in vivo".
    Pedio G; Rüttner JR
    Vasa; 1972; 1(2):135-9. PubMed ID: 5031066
    [No Abstract]   [Full Text] [Related]  

  • 72. Intravenous, long-term infusion in the unrestrained mouse--method.
    Plager JE
    J Lab Clin Med; 1972 Apr; 79(4):669-72. PubMed ID: 5021305
    [No Abstract]   [Full Text] [Related]  

  • 73. The transplantation kinetics of tumour cells.
    Porter EH; Hewitt HB; Blake ER
    Br J Cancer; 1973 Jan; 27(1):55-62. PubMed ID: 4686178
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cancer Stem Cells in Tumor Modeling: Challenges and Future Directions.
    Dogan E; Kisim A; Bati-Ayaz G; Kubicek GJ; Pesen-Okvur D; Miri AK
    Adv Nanobiomed Res; 2021 Nov; 1(11):. PubMed ID: 34927168
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A Mechanism Leading to Changes in Copy Number Variations Affected by Transcriptional Level Might Be Involved in Evolution, Embryonic Development, Senescence, and Oncogenesis Mediated by Retrotransposons.
    Sui Y; Peng S
    Front Cell Dev Biol; 2021; 9():618113. PubMed ID: 33644055
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Combination therapy targeting both cancer stem-like cells and bulk tumor cells for improved efficacy of breast cancer treatment.
    Wang T; Narayanaswamy R; Ren H; Torchilin VP
    Cancer Biol Ther; 2016 Jun; 17(6):698-707. PubMed ID: 27259361
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.
    Rosean TR; Tompkins VS; Tricot G; Holman CJ; Olivier AK; Zhan F; Janz S
    Immunol Res; 2014 Aug; 59(1-3):188-202. PubMed ID: 24845460
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Apoptotic death of cancer stem cells for cancer therapy.
    He YC; Zhou FL; Shen Y; Liao DF; Cao D
    Int J Mol Sci; 2014 May; 15(5):8335-51. PubMed ID: 24823879
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells.
    Tanno T; Lim Y; Wang Q; Chesi M; Bergsagel PL; Matthews G; Johnstone RW; Ghosh N; Borrello I; Huff CA; Matsui W
    Blood; 2014 Jan; 123(5):725-33. PubMed ID: 24345755
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Fact or fiction--identifying the elusive multiple myeloma stem cell.
    Kellner J; Liu B; Kang Y; Li Z
    J Hematol Oncol; 2013 Dec; 6():91. PubMed ID: 24314019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.